Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation

• Published in: Journal of skin cancer Vol. 2019; no. 2019; pp. 1 - 11
• Main Authors: Satzger, Imke, Warnecke, Gregor, Fuge, Jan, Gottlieb, Jens, Leffler, Mareike, Gräger, Nikolai, Gutzmer, Ralf
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2019; Hindawi; John Wiley & Sons, Inc; Wiley
• Subjects: Age; Angiogenesis inhibitors; Cancer therapies; Clinical Study; Drug dosages; Health aspects; Health risks; Immunosuppressive agents; Immunotherapy; Kidneys; Liver; Medical research; Medicine, Experimental; Melanoma; Organ transplant recipients; Patients; Pharmaceutical industry; Risk factors; Skin cancer; Toiletries industry; Transplantation; Transplants & implants; Switzerland; Germany; United States > US
• ISSN: 2090-2905; 2090-2913
• DOI: 10.1155/2019/7089482

Background. Nonmelanoma skin cancer (NSMC) is the most common malignancy after organ transplantation. Lung transplant recipients (LTRs) are particularly prone to develop NMSC as compared to renal or hepatic transplant recipients due to higher dosages of immunosuppression needed. Everolimus, an immunosuppressant used in organ transplant recipients, is thought to inherit a lower risk for NMSC than calcineurin inhibitors, especially in renal transplant recipients. It is currently unknown whether this also applies to LTRs. Objectives. To determine risk factors for NMSC and precancerous lesions after lung transplantation (LTx) and to characterize the effect of everolimus-based regimens regarding this risk. Materials and Methods. 90 LTRs and former participants of the interventional trial “Immunosuppressive Therapy with Everolimus after Lung Transplantation”, who were randomized to receive either an everolimus- or mycophenolate mofetil- (MMF-) based regimen, were enrolled and screened in this retrospective, single-center cohort study. Results. After a median follow-up of 101 months, we observed a prevalence of 38% for NMSC or precancerous lesions. 33% of the patients continuously receiving everolimus from LTx to dermatologic examination compared to 39% of all other patients, predominantly receiving an MMF-based regimen, were diagnosed with at least one NMSC or precancerous lesion (P=.66). Independent risk factors for NMSC or precancerous lesions after LTx were male sex and duration of voriconazole therapy. Conclusion. NMSC or precancerous lesions were very common after LTx, and risk factors were similar to previous reports on LTRs. Everolimus did not decrease this risk under the given circumstances of this study. Patients should be counseled regarding their risk, perform vigorous sunscreen, and undergo regular dermatological controls, regardless of their immunosuppressive regimen.